Rubraca rucaparib

Drug Class

PARP inhibitor

Mechanism

Inhibits poly (ADP-ribose) polymerase (PARP1, PARP2, and PARP3) enzymes, blocking DNA repair pathways and inducing synthetic lethality in BRCA-mutant tumor cells.

Approved Indication

Deleterious BRCA mutation-associated advanced ovarian cancer or recurrent epithelial ovarian cancer, and deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer, per its FDA approval.

What This Means For Patients

Rubraca is an oral targeted PARP inhibitor for patients with advanced ovarian cancer or prostate cancer associated with BRCA gene mutations. It blocks the mechanisms cancer cells use to repair their DNA, and is available for patient access in Boao Lecheng.

Regulatory Approvals

• FDA — approved (2016) — label

Pivotal Clinical Evidence

• TRITON3 — Fizazi et al., N Engl J Med 2023 (NCT02975934) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf